Submicroscopic Deletion of FGFR1 Gene Is Recurrently Detected in Myeloid and Lymphoid Neoplasms Associated with ZMYM2-FGFR1 Rearrangements: A Case Study

a Department of Laboratory Medicine, School of Medicine, Kyung Hee University, b Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul , Departments of c Laboratory Medicine and d Pathology, Inje University College of Medicine, Busan , and e School of Life Science and Biotechnology, Kyungpook National University, Daegu , Republic of Korea; f Institute of Pharmaceutical Biology, ZAFES, Diagnostic Center of Acute Leukemia, Goethe University of Frankfurt, Frankfurt/Main , Germany

[1]  S. K. Baek,et al.  Submicroscopic Deletion of RUNX1T1 Gene Confirmed by High-Resolution Microarray in Acute Myeloid Leukemia with RUNX1/RUNX1T1 Rearrangement , 2011, Acta Haematologica.

[2]  R. Marschalek,et al.  De novo Acute Myeloid Leukemia Associated with t(11;17)(q23;q25) and MLL-SEPT9 Rearrangement in an Elderly Patient: A Case Study and Review of the Literature , 2011, Acta Haematologica.

[3]  R. Marschalek,et al.  A novel PML-ADAMTS17-RARA gene rearrangement in a patient with pregnancy-related acute promyelocytic leukemia. , 2011, Leukemia research.

[4]  David T. W. Jones,et al.  Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma , 2011, Acta Neuropathologica.

[5]  Hee-Jin Kim,et al.  Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia , 2011, Annals of Hematology.

[6]  J. Huret.  FGFR1 (Fibroblast Growth Factor Receptor 1) , 2011 .

[7]  M. Pébusque.  FGFR 1 ( Fibroblast Growth Factor Receptor 1 ) , 2011 .

[8]  Jae Jin Lee,et al.  FISH-negative cryptic PML-RARA rearrangement detected by long-distance polymerase chain reaction and sequencing analyses: a case study and review of the literature. , 2010, Cancer genetics and cytogenetics.

[9]  L. Medeiros,et al.  8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.

[10]  R. Marschalek,et al.  Three-way translocation involving MLL, MLLT1, and a novel third partner, NRXN1, in a patient with acute lymphoblastic leukemia and t(2;19;11) (p12;p13.3;q23). , 2010, Cancer genetics and cytogenetics.

[11]  Min Jin Kim,et al.  ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. , 2010, Cancer genetics and cytogenetics.

[12]  R. Marschalek,et al.  CASP8AP2 is a novel partner gene of MLL rearrangement with t(6;11)(q15;q23) in acute myeloid leukemia. , 2009, Cancer genetics and cytogenetics.

[13]  T. Dingermann,et al.  An Interstitial Deletion at 3p21.3 Results in the Genetic Fusion of MLH1 and ITGA9 in a Lynch Syndrome Family , 2009, Clinical Cancer Research.

[14]  M. Krzywinski,et al.  New insights to the MLL recombinome of acute leukemias , 2009, Leukemia.

[15]  D. Birnbaum,et al.  Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder. , 2007, Cancer genetics and cytogenetics.

[16]  R. Pieters,et al.  Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Fabbro,et al.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Kim,et al.  Clinical Implication of the Deletion Status of ABL-BCR on Derivative Chromosome 9 in Chronic Myelogenous Leukemia , 2002 .

[19]  A. Reiter,et al.  The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1 , 2002, Acta Haematologica.

[20]  M. Leversha,et al.  Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. , 2000, Blood.

[21]  R. Aguiar,et al.  Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. , 1998, Blood.

[22]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Aguiar,et al.  Consistent Fusion of ZNF 198 to the Fibroblast Growth Factor Receptor-1 in the t ( 8 ; 13 ) ( p 11 ; q 12 ) Myeloproliferative Syndrome , 1998 .